BioSpace News Archive

Nyquist Data, Inc., the leading intelligence platform for medical technology, announces today that it has entered into a commercial partnership with Clarivate Plc, a global leader in providing trusted information and insights to accelerate the pace of innovation.

Deepcell, a life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, today announced the appointment of Kevin Farrell as SVP, Operations.

Increasing prevalence of chronic diseases across the globe, rising need for automated solutions to manage large patient database, and increasing number of EHR service providers are some key factors expected to drive global Electronic Health Records market growth.

Increasing prevalence of cancer, neurological, cardiovascular and urological diseases, rising volumes of radiological procedures, and rapid adoption of AI in radiology are some key factors expected to drive global market growth.

Rising prevalence of cerebral palsy across the globe, increasing healthcare spending, and rising investments in R&D activities are some key factors expected to drive global Cerebral Palsy market growth.

Increasing prevalence of chronic diseases, rising geriatric population, and rapid advancements in electroceutical devices are some key factors expected to drive global Bioelectric Medicine market growth.

Scilex Holding Company has entered into a license and commercialization agreement with RxOmeg Therapeutics LLC, a/k/a Romeg Therapeutics, LLC, for the exclusive right to market and distribute in the US Gloperba, an oral solution for adults suffering from gout.

Eurocine Vaccines AB (“Eurocine Vaccines”) hereby announces that the company has entered into a research and collaboration agreement with Redbiotec AG (“Redbiotec”).

Adial Pharmaceuticals, Inc. today announced patent number 11,351,154 was issued on June 7, 2022, by the U.S. Patent and Trademark Office.

NeuroSigma, Inc., a bioelectronic medical device company, today announced that a team at the University of California, Los Angeles (UCLA) led by Professor Sandra Loo received a National Institutes of Health (NIH) grant to conduct a double-blind randomized controlled trial of eTNS for pediatric attention-deficit/hyperactivity disorder (ADHD).